PulseSight Therapeutics SAS has taken a significant step forward in addressing age-related macular degeneration (AMD) by submitting a Clinical Trial Authorization (CTA) to France's national drug regulatory agency for its lead candidate PST-611.
Novel Therapeutic Approach for Retinal Disease
The Paris-based ophthalmology biotech company is developing PST-611 as a non-viral vectorized therapy specifically targeting dry AMD and Geographic Atrophy (GA), conditions for which treatment options remain limited. The therapy employs an innovative transferrin vectorization approach combined with minimally-invasive delivery technology, potentially offering advantages over current treatment modalities.
Phase I Trial Design
The planned first-in-human trial, designated PST-611-CT1, will implement a single ascending dose design to evaluate the safety and tolerability profile of PST-611. This initial clinical investigation represents a crucial milestone in the development pathway for this novel therapeutic approach.
Addressing an Unmet Medical Need
Geographic Atrophy, an advanced form of dry AMD, affects millions of people worldwide and is a leading cause of vision loss among older adults. Current treatment options for GA are extremely limited, making the development of new therapeutic approaches particularly significant for this patient population.
Technology Platform Potential
The company's proprietary transferrin vectorization technology platform, coupled with its minimally-invasive delivery approach, could potentially overcome several challenges associated with treating retinal diseases. This includes improved targeting of affected tissues and reduced burden of treatment administration.
The advancement of PST-611 into clinical development marks an important milestone not only for PulseSight Therapeutics but also for the field of ophthalmology, as it represents a novel approach to treating degenerative retinal conditions.
